These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20486301)

  • 1. Vulvovaginal Atrophy.
    Kellogg-Spadt S
    Adv Nurse Pract; 2010 Apr; 18(4):31-32, 34, 55. PubMed ID: 20486301
    [No Abstract]   [Full Text] [Related]  

  • 2. Estrogen for vulvovaginal symptoms: how low can you go?
    Brzezinski A; Benshushan A
    Menopause; 2009; 16(5):848-50. PubMed ID: 19564805
    [No Abstract]   [Full Text] [Related]  

  • 3. Vulvovaginal atrophy: new and upcoming approaches.
    Simon JA
    Menopause; 2009; 16(1):5-7. PubMed ID: 19131842
    [No Abstract]   [Full Text] [Related]  

  • 4. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
    Simon JA; Reape KZ; Wininger S; Hait H
    Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
    Tan O; Bradshaw K; Carr BR
    Menopause; 2012 Jan; 19(1):109-17. PubMed ID: 22011753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations.
    Lev-Sagie A
    Clin Obstet Gynecol; 2015 Sep; 58(3):476-91. PubMed ID: 26125962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective estrogen receptor modulators and vulvovaginal atrophy: can we improve the lives of our patients with new therapeutic options?
    Shulman LP
    Menopause; 2010; 17(3):452-3. PubMed ID: 20464782
    [No Abstract]   [Full Text] [Related]  

  • 9. Estrogen and its effect on vaginal atrophy in post-menopausal women.
    Kelley C
    Urol Nurs; 2007 Feb; 27(1):40-5. PubMed ID: 17390926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-hormonal approaches for the treatment of vulvovaginal atrophy: the choice between hyaluronic acid and glycerin.
    Palacios S
    Gynecol Endocrinol; 2020 Oct; 36(10):847-848. PubMed ID: 32873079
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
    North American Menopause Society
    Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women.
    Levine KB; Williams RE; Hartmann KE
    Menopause; 2008; 15(4 Pt 1):661-6. PubMed ID: 18698279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vulvovaginal complaints.
    Mehta A; Bachmann G
    Clin Obstet Gynecol; 2008 Sep; 51(3):549-55. PubMed ID: 18677149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vulvovaginal dryness and itching.
    Margesson LJ
    Skin Therapy Lett; 2001 Sep; 6(10):3-4. PubMed ID: 11685276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
    Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
    Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review.
    Rueda C; Osorio AM; Avellaneda AC; Pinzón CE; Restrepo OI
    Climacteric; 2017 Aug; 20(4):321-330. PubMed ID: 28622049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personal opinion: Treatment of vulvovaginal atrophy--are hidden interests and misinformation preventing better management?
    Pines A; Sturdee DW
    Climacteric; 2015; 18(6):802-4. PubMed ID: 26397968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G; Bobula J; Mirkin S
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why the product labeling for low-dose vaginal estrogen should be changed.
    Manson JE; Goldstein SR; Kagan R; Kaunitz AM; Liu JH; Pinkerton JV; Rebar RW; Schnatz PF; Shifren JL; Stuenkel CA; Gass ML; Utian WH;
    Menopause; 2014 Sep; 21(9):911-6. PubMed ID: 25140698
    [No Abstract]   [Full Text] [Related]  

  • 20. Vulvovaginal atrophy: a common--and commonly overlooked--problem.
    Hohenhaus MH
    Med Health R I; 2011 May; 94(5):138-40. PubMed ID: 21710922
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.